Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial
Jeongkuk Seo, Won Seog Kim, Jin Seok Kim, Seok Jin Kim, Jae Hoon Lee, Jun Shik Hong, Gyeong Won Lee, Sung Yong Oh, Ji Hyun Lee, Dok Hyun Yoon, Won Sik Lee, Hyo Jung Kim, Jae Yong Kwak, Hye Jin Kang, Jae Cheol Jo, Yong Park, Ho Sup Lee, Hyo Jin Kim, Cheolwon Suh
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial'. Together they form a unique fingerprint.